Rentschler Biopharma is a global CDMO specialising in drug substance manufacturing for biologics, including monoclonal antibodies and other complex molecules.
The CDMO space is crowded, increasingly competitive, and more capital-intensive than ever. Where can a mid-sized company like Rentschler Biopharma position itself and win against larger players? What really differentiates you?
Consolidation has accelerated in recent years, especially post-COVID, but Rentschler Biopharma has a long foundation to stand on. We were one of the first to establish a biotech CDMO business, beginning about 50 years ago with products like Interferon, and eventually shifting fully into services because developing our own products was too risky for a mid-sized business. That history created deep expertise in complex molecules, and clients consistently highlight our quality, flexibility, and reliability. We understand the full value chain—from sequence to launch—and have strong regulatory experience, with successful audits from FDA, EMA, Japanese, Brazilian, and other authorities.
What also differentiates us is stability. As a fifth-generation, family-owned company, we provide long-term partnership security at a time when constant M&A disrupts teams, changes structures, and slows projects. Clients value that continuity, especially when moving complex programs quickly to market. We stay focused on what we do best—drug substance manufacturing for monoclonal antibodies and other complex molecules—while remaining large enough to stay agile and close to clients.
Long-term partnerships seem to be becoming more common in the industry. Why are pharma and biotechs moving away from project-based work?
The old model of treating CDMOs as simple “extended workbenches” is over.
As molecules grow more complex, companies recognise that no one organisation—large or small—has every capability in-house. They rely increasingly on partners with specialised expertise. Some CDMOs claim to be true one-stop shops, but often the value doesn’t materialize because acquisitions create scattered sites, inconsistent cultures, and no single face to the customer. Add the pressures from private equity ownership and the result is instability that clients want to avoid.
Long-term partnerships minimise disruption, reduce regulatory risk, and avoid delays that can cost companies tens of millions per month. They ensure process continuity from Phase 1 through Phase 3, and clients increasingly prefer specialists who can deliver high yields, robust processes, and smooth regulatory interactions. For example, through improved cell lines we have achieved double-digit gram-per-litre yields, potentially reducing the number of required batches from double-digit to low single-digit—major savings in both cost and time. When development timelines stretch five to eight years, consistency becomes critical, and long-term collaboration delivers that.
You seem to have a principled reluctance to scale for its own sake. Is the intention to remain a mid-sized CDMO?
We believe growth must be consistent and sustainable rather than growth for its own sake. The industry has shifted fundamentally: diseases are now broken into far more precise indications, meaning smaller patient populations and much less material needed per programme. Blockbuster-scale production is no longer the norm. Rising yields also reduce the need for high-volume manufacturing. Combined, this means the value lies not in being the largest player but in being highly effective in mid-scale, high-quality production.
Small and mid-sized biotechs excel in understanding disease biology and targets, but they typically lack CMC and manufacturing expertise. That is where we partner—bringing process know-how, early-stage development capabilities, and the ability to design robust processes from the start. Remaining mid-sized allows us to stay close to clients, adapt quickly to variation between programmes, and avoid the complexity and rigidity that can come with very large-scale operations.
Rentschler Biopharma was recently named Manufacturer of the Year for Central Massachusetts. Why do you think you received that recognition, and what drove your investment in the US facility?
Our strategic review in 2018 identified increasing our US footprint as an essential next step. Clients wanted production in the US—the world’s largest market and a centre of innovation—and we committed to it with the acquisition of a site in Milford, MA, in 2019 and the largest investment in our company history, in building a modern new line. That decision later gained tailwinds from geopolitical developments such as the Biosecurity Act discussions and new tariffs, which pushed many clients to diversify away from other CDMOs.
The award recognizes our advanced facility, commitment to workforce development, and positive impact on the local biomanufacturing community. Furthermore, it reflects how quickly and successfully we brought the site online. Our engineering run was successful on the first attempt—very rare—as well as our first GMP run. The credit goes entirely to the team in Milford, MA, whose passion and expertise are evident to our clients when they visit. It demonstrated that our quality isn’t just a German legacy—it’s deeply embedded in the people and the culture at our US facility.
Will the US administration’s reshoring push and “America First” policies influence your long-term investment split between Germany and Massachusetts?
Our investment decisions follow client needs and long-term strategy, not geopolitical developments. The pharmaceutical market is centred in Europe and the US, with growing innovation in Asia, and our goal is to serve clients where they are while providing a reliable, transatlantic network. The Massachusetts investment was made well before tariff policies emerged, and while those developments accelerated demand for US production, our decision was strategic, not reactive.
We continue to invest heavily in Germany as well. After significantly improving productivity without adding new lines, we are expanding our Laupheim site with a new buffer and media station—our largest investment in Germany—to prepare for increased capacity and faster digitalisation. Both sites remain critical to our long-term plan, enabling us to offer modern, flexible, and resilient manufacturing across regions.
Are you looking to build AI capabilities internally or through partnerships?
In my opinion, AI is a tool, not a standalone system you buy. It’s about identifying the right use cases and integrating the right technologies. We are in discussion with multiple potential partners to explore case studies and tools, while also assessing what capabilities should remain internal. We aim to become a highly effective user of AI across development, manufacturing, and regulatory operations.
The way I see it, the biggest industry impact could be in production in general, which could represent 40% of a roughly $250 billion annual value opportunity by 2030. AI could even cut clinical trial timelines in half by improving patient recruitment, which would shift expectations for manufacturing speed. That means we must prepare to produce faster, automate more, and redeploy highly trained staff to higher-value tasks. Our innovation task force ensures we stay tightly connected to emerging technologies, universities, startups, and networks so we remain ahead of these shifts.
Looking ahead 12 to 24 months, what are you most excited about at Rentschler Biopharma?
I’m excited to build on the momentum we’ve created—expanding client value, strengthening reliability and quality, and continuing to grow with our partners. Our goal isn’t to be the biggest CDMO but to be among the top in client satisfaction and trust. We have many opportunities in the market, and the next years will focus on refining our services and building an even stronger organisation.
I’m also energized by the potential of new technologies, especially AI, and how they can streamline development timelines, manufacturing efficiency, and regulatory pathways. We’ve already contributed meaningfully—for example, supporting in production of over 2 billion COVID-19 vaccine doses for BioNTech—and the objective remains the same: help clients bring medicines to patients faster, reduce disease burden, and make a real impact. That is what motivates us for the years ahead.
